Physician profile
Muhammad Ejaz
NPI 1336182179
$1,935.19
in general payments reported to CMS, 2019-2025
24 companies · $976 in 2025
The $976 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $243 · 2024: $717 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $367.64 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $196.48 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $189.97 | 2025 | Dovato, Rukobia, Cabenuva |
| Inspire Medical Systems, INC. | $154.62 | 2025 | Inspire |
| Abbvie INC. | $152.92 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.11 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $99.64 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $87.49 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $84.32 | 2025 | Voquezna |
| Corcept Therapeutics | $75.12 | 2024 | Korlym |
| Pfizer INC. | $55.38 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.33 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $36.81 | 2025 | Gemtesa |
| Amgen INC. | $34.90 | 2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.27 | 2024-2025 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $26.72 | 2025 | Skyclarys |
| Medtronic, INC. | $23.82 | 2025 | Inceptiv |
| Dexcom, INC. | $21.48 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $20.62 | 2024 | Bd Max System, Bd Max Instrument |
| Merck Sharp & Dohme LLC | $17.44 | 2025 | Pifeltro, Delstrigo |
| Otsuka America Pharmaceutical, INC. | $15.40 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.67 | 2024 | Gvoke Hypopen |
| Pharming Healthcare, INC. | $14.47 | 2024 | Ruconest |
| Glaxosmithkline, LLC. | $13.57 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ejaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.